-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
T-cells are natural warriors of anti-tumor in the body and can rely on their subjects (TCR) to identify tumor antigens. How to empower T cells and make them accurately and continuously "kill" tumor cells in the body? Our scientists have given a new answer.Molecular Cell Science Innovation Center for Excellence (Bioindustification and Cell Institute, referred to as the Center for Molecular Cell Excellence) Xu Wei team, Peking University Medical Department Huang Chaolan team and the University of California, San Diego Whinf team, from the basic research of T cell signal transduce, developed a new method of CAR-T cell therapy. The results were published online late on July 29 in the international academic journal Cell.
TCR can identify tumor antigens, but not all TCR can do this. Therefore, scientists use genetic engineering technology for T cells to add a "sharp weapon" - specific identification of tumor antigens of the chimed antigens (CAR), modified T cells can accurately "kill" tumor cells in the body. But CAR-T cell therapy also has a lot of drawbacks.
"CAR-T cells are overactive" and can easily cause cytokine storms, triggering uncontrollable risks to the immune system, and CAR-T cells are not sustainable in the body, so long-term monitoring of tumor cells can lead to tumor recurrence, " Xu said. In
new study, researchers used immunology, mass spectrometology, biochemistry, biophysics and other techniques to study the signal transducing mechanism of CD3e, a key signal molecule in TCR. By developing a new method of absolute quantitative proteomics based on mass spectrometry (TIMLAQ-MS), Huang Chaolan team revealed the dynamic phosphorylation modification of Tyrosine compound tyrosine in antigen stimulation of Tyrosine, and analyzed the mysteries of phosphorylation characteristics in different CD3 chain ITM domains. The Xu wei team and the Whinf team found that single phosphorylation CD3e ITAM recruited the inhibitory signal molecule Csk, while the active signal molecule PI3K could be recruited through its BRS signal base sequence. "The two signal molecules recruited by CD3e function oppositely, Csk is like 'brake', PI3K is like 'throttle', making clinical treatment controllable, " Xu explains.
is integrated into CD3e in the 28Z CAR currently used clinically to reduce cytokine secretion and promote cell growth and survival, improving its sustainability overall.
xu said that in the mouse model, the "upgraded" E28Z CAR-T anti-tumor activity increased significantly compared to the "original". "At this time, our research is still in the mouse experimental stage, and given its promising application in hematoma and solid tumor treatment, it is our goal to apply the results to the clinic at an early stage."
the paper on the land of the motherland, people's livelihood depends on. "Our science and technology to be transformed into productivity, although the ultimate goal is to apply, but can not be separated from basic research, the source of living water." "No matter how the evaluation system changes, the importance of innovation at the source of basic research will not change, and this finding is a good example," said Li Lin, a
academician and director of the Academic Committee of the Center for Molecular Cell Excellence. "
" hope that our scientists this scientific research results can one day feed the community, for taxpayers, for the vast number of patients to bring good news. Liu Xiaolong, director of the Center of Excellence for Molecular Cell Science, said.
relevant paper information: